Millions of Eye Drops Recalled Across Dozens of Brands

Supply chain vulnerabilities and lack of transparency raise concerns about consumer healthcare safety

Apr. 10, 2026 at 8:22am

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of an eye dropper bottle, with the internal components rendered in glowing lines against a dark background, conveying the vulnerability of everyday healthcare products.An X-ray view of an eye dropper bottle exposes the fragility of consumer healthcare supply chains, where a single manufacturing lapse can jeopardize public trust.Pomona Today

Millions of eye drops manufactured by K.C. Pharmaceuticals in Pomona, California have been recalled across dozens of store brands sold at major retailers like Walgreens, CVS, Kroger, and Meijer. The recall exposes systemic issues in the consumer healthcare supply chain, including a lack of transparency about affected products and a need for stronger quality assurance and communication protocols.

Why it matters

This recall highlights how a single manufacturing issue can ripple across the entire retail ecosystem, undermining consumer trust in everyday healthcare products. It also raises questions about accountability, as the opacity of supply chains makes it unclear whether retailers or the manufacturer bears more responsibility for product safety.

The details

The FDA recall notice covers eight different product categories, including Sterile Eye Drops A.C. and Artificial Tears Sterile Lubricant, all linked to the Pomona-based manufacturer. This reveals how a single production line or batch can impact a wide range of brands and outlets, from big chains to regional independents. The lack of a press release and KC Pharmaceuticals' failure to respond to inquiries has also created a vacuum, eroding trust and fueling anxiety among consumers.

  • The FDA issued the recall notice on April 10, 2026.

The players

K.C. Pharmaceuticals

The Pomona, California-based manufacturer responsible for producing the recalled eye drop products.

FDA

The U.S. Food and Drug Administration, which issued the recall notice and is overseeing the investigation.

Got photos? Submit your photos here. ›

What they’re saying

“This recall underscores a persistent opacity in supply chains: you may own a 'trusted' bottle labeled with your favorite retailer, yet its provenance could be multiple steps removed from the actual manufacturer.”

— Kimberely Baumbach CPA, Product Banking Analyst

What’s next

The FDA has not yet provided a list of specific UPCs for affected products, making it difficult for consumers to identify which bottles they should discard. Retailers are also expected to provide more guidance on replacement options and safe disposal of recalled items.

The takeaway

This recall highlights the need for greater transparency, accountability, and rapid response protocols in the consumer healthcare supply chain. Stronger batch-level visibility, independent quality testing, and clear communication from both regulators and manufacturers could help restore trust and protect public health when issues arise.